
News|Articles|March 7, 2024
Boehringer Ingelheim to Cap Out-of-Pocket Cost for Inhalers at $35
Advertisement
Beginning June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for all Boehringer Ingelheim inhalers to treat asthma and chronic obstructive pulmonary disease (COPD). Included are:
- Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol
- Combivent Respimat® (ipratropium bromide and albuterol) Inhalation Spray
- Spiriva HandiHaler(tiotropium bromide inhalation powder)
- Spiriva Respimat 1.25 mcg (tiotropium bromide) Inhalation Spray
- Spiriva® Respimat 2.5 mcg (tiotropium bromide) Inhalation Spray
- Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray
- Striverdi Respimat (olodaterol) Inhalation Spray
The company said in a press release that it will decrease the list price on some of its inhaler products and will continue providing rebates off the list price of its medicines to insurers and pharmacy benefits managers.
Advertisement
Related Content
Advertisement





FDA approves first biosimilars interchangeable with Simponi/Simponi Aria
Published: | Updated:
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends
2
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
FDA approves first treatment for chronic hepatitis D virus
5






















